Tumor microenvironment (TME) is commonly implicated in regulating the growth of tumors, but whether it can directly alter the genetics of tumors is not known. Genomic instability and dendritic cell (DC) infiltration are common features of several cancers including myeloma (MM). Mechanisms underlying genomic instability in MM are largely unknown. Here we show that interaction between myeloma and DCs but not monocytes, leads to rapid induction of the genomic mutator AID and AID-dependent DNA double-strand breaks (DSBs) in myeloma cell lines as well as primary MM cells. Both myeloid as well as plasmacytoid DCs have the capacity to induce AID in tumor cells. The induction of AID and DSBs in tumor cells by DCs requires DC-tumor contact and is inhibited by blockade of RANK/RANKL interactions. AID-mediated genomic damage led to altered tumorigenicity and indolent behavior of tumor cells in-vivo. These data demonstrate a novel pathway for the capacity of DCs in the TME to regulate genomic integrity. DC-mediated induction of AID and resultant genomic damage may therefore serve as a double-edged sword and targeted by approaches such as RANKL inhibition already in the clinic.
Dendritic Cell-Mediated Activation induced cytidine deaminase (AID)-Dependent

Induction of Genomic Instability in Human Myeloma
Srinivas Koduru 
Abstract:
Tumor microenvironment (TME) is commonly implicated in regulating the growth of tumors, but whether it can directly alter the genetics of tumors is not known. Genomic instability and dendritic cell (DC) infiltration are common features of several cancers including myeloma (MM). Mechanisms underlying genomic instability in MM are largely unknown. Here we show that interaction between myeloma and DCs but not monocytes, leads to rapid induction of the genomic mutator AID and AID-dependent DNA double-strand breaks (DSBs) in myeloma cell lines as well as primary MM cells. Both myeloid as well as plasmacytoid DCs have the capacity to induce AID in tumor cells. The induction of AID and DSBs in tumor cells by DCs requires DC-tumor contact and is inhibited by blockade of RANK/RANKL interactions. AID-mediated genomic damage led to altered tumorigenicity and indolent behavior of tumor cells in-vivo. These data demonstrate a novel pathway for the capacity of DCs in the TME to regulate genomic integrity. DC-mediated induction of AID and resultant genomic damage may therefore serve as a double-edged sword and targeted by approaches such as RANKL inhibition already in the clinic. MGUS are poorly understood. One candidate is activation induced cytidine deaminase (AID) , which is essential for somatic hypermutation and class switch recombination 2, 3 .
Mistargeting of AID has been implicated in oncogenic mutations and chromosome translocations in both lymphoid and non-lymphoid tumors [3] [4] [5] . However, prior studies had failed to detect AID in MM cell lines, implying that other pathways may be involved in mediating genomic instability in this tumor 6 . Several studies have emphasized the importance of tumor microenvironment in the biology of human MM 7 . While the role for tumor microenvironment (TME) in regulating tumor growth is well established, whether and how it might directly alter the genetics of tumors is not known. Several studies have shown that tumor lesions in MM are highly infiltrated by dendritic cells (DCs) [8] [9] [10] . In prior studies we had observed that the interaction between DCs and MM cells led to aberrant re-expression of BCL6 in MM cells, a gene typically silenced during normal plasma cell differentiation 11 . Therefore we tested whether this interaction could also induce the expression of AID in tumor cells. DCs were generated from purified blood monocytes as described earlier 11, 12 . In brief, monocytes isolated using CD14 microbeads (Miltenyi Biotec, Auburn, CA) were cultured in the presence of granulocyte monocyte colony stimulating factor (GM-CSF; 20 ng/mL; Genzyne) and IL-4 (20 ng/mL; R&D Systems, Minneapolis, MN). DCs were typically used on day 5 or 6 of culture. For some experiments, DCs were matured by the use of inflammatory cytokines or lipopolysaccharide (LPS, 20 ng/mL; Sigma-Aldrich, St Louis, MO) as described 12, 13 . Macrophages were generated from CD14+ monocytes cultured After washing with 1x PBS, slides were mounted and dried. Fluorescence was viewed with LSM 510 meta-confocal microscope (Zeiss). Digital images were captured at random using LSM Image software and analyzed using Zeiss LS Image Browser and cells with γ-H2AX foci formation were manually counted. were washed and stained with secondary antibody (Anti-Rat; Dako), followed by DAB and hematoxylin. Images were taken using a Nikon camera.
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Statistical analysis
Data from different experimental groups were compared using the Student's t test, and significance was set at P < 0.05. All the experiments were repeated minimum of three times for reproducibility. . Co-culture of several MM cell lines with human monocyte-derived DCs (MoDCs) led to clear induction of AID transcripts (Fig 1a) . Importantly, co-culture of tumor cells with monocytes did not lead to similar induction of AID, indicating that this effect was specific to DCs (Fig 1b) . DCs were also more efficient than macrophages at inducing AID (Fig 1c) . DC-mediated induction of AID expression was also confirmed at the protein level by western blot as well as by flow cytometry (Fig 1d, 1e) . The level of AID expression in MM cells was lower (about 25%) than in lymphoid cells such as Ramos. Mo-DCs serve as a model for DCs generated in the setting of inflammation but may differ from circulating DCs 17 . Therefore, we also tested the capacity of circulating human DC subsets to induce the expression of AID in tumor cells. Both myeloid and plasmacytoid DCs are known to be enriched in MM lesions [8] [9] [10] 18 , and both were capable of inducing the expression of AID in MM cells (Fig 1f) . The capacity of DCs to induce AID was not restricted to MM cells, as co-culture with DCs also led to AID induction in breast cancer (MCF-7) cells (Fig 1g) .
The expression of AID protein in primary MM cells in situ and the infiltration of MM lesions by interdigitating DC-SIGN+ dendritic cells was confirmed by immunohistochemistry (Fig 2a) . Culture of freshly isolated primary MM cells with DCs also led to clear induction of AID expression (Fig 2b) . Furthermore, co-culture of DC-SIGN+ DCs isolated from the bone marrow with MM cells also led to the induction of For personal use only. on July 15, 2017. by guest www.bloodjournal.org From AID (Fig 2c) . Taken together, these data show that interaction between DCs and tumor cells leads to the induction of AID in tumor cells, and that AID is indeed expressed by primary human MM cells in-situ found in proximity to interdigitating DCs.
In order to better understand the underlying mechanism, we first tested whether the induction of AID was mediated by soluble factors / cytokines released by DCs or required cell to cell contact. Separation of tumor cells and DCs in transwell inserts abrogated the induction of AID, indicating the need for cell contact (Fig 3a) . Indeed, AID expression depends on continued cell contact as further culture of tumor cells reisolated after initial co-culture with DCs led to loss of AID expression (Fig 3b) . The capacity of DCs to induce AID was linked to their activation status. Maturation of DCs by either inflammatory cytokines or LPS abrogated their capacity to induce AID indicating that the properties of DCs had a major impact on their ability to induce AID (Fig 3c) . One of the major cell surface changes common to both forms of DC maturation relates to marked alteration of RANKL/osteoprotegerin (OPG) ratio 19 . Therefore we evaluated a role for RANKL mediated signaling in the induction of AID. Co-culture of MM cells with DCs was found to lead to an increase in RANKL expression in tumor cells (Fig 3d) . One of the major signaling pathways activated by RANKL-mediated signaling is the activation of NF-κB, which is known to induce AID expression 3 . Co-culture of MM cells with DCs also led to an increase in pp65, consistent with NF-κB activation (Fig 3e) . Pretreatment with RANKL inhibitor OPG led to inhibition of DC-mediated induction of AID (Fig 3f) as well as suppression of DC-mediated activation of NF-κB (Fig 3g) . Simply adding soluble RANKL to MM cells did not lead to similar induction of AID (data not shown), consistent (Fig 3a) and prior studies regarding the potency of cell associated RANKL compared to soluble RANKL 20 . In order to further confirm the role of RANKL, we also tested the effect of anti-RANKL antibody. Pretreatment with anti-RANKL antibody also led to inhibition of AID (Fig 3h) , as seen with OPG. Together, these data therefore demonstrate an important role for cell-associated RANKL-mediated signaling in the induction of AID in these studies. It is notable that the inhibition of AID after RANKL blockade is not complete, suggesting a potential role for other pathways in this effect as well.
One of the consequences of AID-induced genomic damage involves the formation of DNA DSBs 21, 22 . Phosphorylation of histone H2AX is an early cellular marker of induction of DNA DSBs 23 . Interaction between DCs and myeloma cells led to the induction of multiple γ-H2AX foci, as detected by immunofluorescence (Fig 4a) as well as phospho-H2AX detected by western blot (Fig 4b) . Inhibition of AID by RNA interference led to clear inhibition of DC-mediated induction of γ-H2AX foci in tumor cells (Fig 4c) , indicating a direct role for AID in this process and confirming that the level of AID induction observed in these experiments was sufficient to mediate damage to the genome. Formation of γ-H2AX foci was also inhibited by pretreatment with OPG (Fig 4d) consistent with its ability to inhibit AID (Fig 3f) . Together these data demonstrate that DC-mediated induction of AID can lead to significant genomic damage in tumor cells.
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From AID-mediated genomic damage may drive genetic evolution of tumors. However in the short term, genomic damage can also lead to cell cycle arrest, cell death or senescence. In order to test the functional effects of DC or AID-mediated genomic damage, we analyzed the capacity of tumor cells to grow in immune-deficient mice.
Injection of control U266 cells led to formation of visible tumors that stained for CD138+ tumor cells (Fig 5a) and associated disease related morbidity resulting in diminished survival (Fig 5b) . In contrast, mice injected with tumor cells that encountered DNA damage after exposure to DCs did not develop visible tumors and exhibited better survival (Fig 5b, 5c ). However these mice did carry small numbers of foci of CD138+ tumor cells without the formation of overt tumor masses. These foci were predominantly localized to the subcapsular region in the spleen (Fig 5c) . Together these data show that DC / AID-mediated genomic damage leads to altered tumorigenicity and induction of tumor cells with an indolent behavior in vivo.
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Discussion:
Herein we have shown that the interactions between tumor cells and DCs can induce AID-dependent genomic damage in human MM and that AID is detectable in primary MM cells in situ. DCs are known to be enriched in several human tumors including MM and primarily studied for their effects on tumor immunity, growth regulation or osteoclastogenesis, but not direct effect on genetics of tumors [8] [9] [10] [11] 18, [24] [25] [26] [27] . AID can also play an important role in the development of chromosome translocations (particularly those involving immunoglobulin heavy chain locus), oncogenic mutations, as well as DNA demethylation that may contribute to carcinogenesis 21, 28 . AID may also be important for murine myeloma models. It is also of note that mistargeting of AID activity was utilized to develop a mouse model for MM 29 . AID activity has also been linked to the development of pristane oil induced plasmacytomas in mice 30, 31 . Together, these data therefore suggest that tumor-DC interactions and AID activity may be at the heart of pathogenesis of human and murine MM.
These data show that signals from TME may be critical regulators of AID expression in tumor cells. Expression of AID in chronic lymphocytic leukemia was also recently linked to an activated microenvironment, although the nature of specific cell types or underlying mechanisms involved were not elucidated 32 . 33, 34 . Further study is needed to explore the role of AID in other tumors. As the expression of AID may be primarily microenvironment-dependent as shown here for MM, it would be essential to test AID expression and activity in-situ in additional primary human tumors (as opposed to isolated tumor cells) in order to better understand the possible role of AID in the pathogenesis of human tumors.
While prior studies have mostly emphasized trophic effects of DCs on tumors 8, 10, 11, 26 , these data show that DCs can also induce genomic damage. The capacity of DCs to induce genomic damage may involve several DC subsets and includes plasmacytoid DCs also known to be enriched in MM However AID-mediated genomic damage may serve as a double-edged sword and can also engage protective cell cycle checkpoints due to DNA damage response leading to the activation of innate immunity 35, 36 . Our data show that AID- 
concept that specific signals from TME (such as via DCs or involving RANKL signaling) can regulate the expression of AID and induce genomic damage raises the possibility that interrupting such signals may also impact genetic instability of tumors in vivo. It will be of interest to test whether current approaches to block RANK-RANKL interactions already in the clinic will also impact genetic evolution of human tumors, particularly if applied early.
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